News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News Robert Stewart Jr., Virginia Entrepreneur, Launches Scholarship and Grant Programs to Support College Students Nationwide News TSplus Releases Server Monitoring Version 6 – A Major Step Forward in Remote Infrastructure Management News Hola Prime Launches Performance Coaching Initiative to Tackle the #1 Barrier to Trader Success: The Mind News Babelio Wraps a Dynamic Showcase of Parenting Essentials at ABC Kids Expo 2025 News Enablence Technologies Inc. Announces Third Quarter Fiscal 2025 Financial Results News Eddy Smart Home Solutions Ltd. Announces Q1/2025 Financial Results
